



## Mithra Releases Invitation to its General Shareholders' Meeting

Liege, Belgium, 25 April 2023 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces the invitation to its general shareholders' meeting that will be held on **Thursday May 25 2023** at 2:00 PM (CEST).

The notice for the General Meeting including a description of the formalities to participate in the meeting is available on the website [investors.mithra.com](https://investors.mithra.com).

### Admission requirements

As referred in the meeting's invitation published in the Belgian press, the right to participate in the general shareholder's meeting and to vote is subject to the prior registration of the shares under the shareholder's name on **11 May 2023 at midnight** (CEST) (the "**Record Date**"), either by way of registration on the company's share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the general meeting. Only persons who are shareholders on the Record Date are entitled to vote at the general meeting.

A certification is delivered to the shareholder by the settlement institution or certified account holder which certifies the number of dematerialized shares registered in its accounts under the name of the shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the general meeting.

The shareholder indicates his willingness to participate in the General Meeting by **19 May 2023** at the latest. This must be done by email to [corporate.secretary@mithra.com](mailto:corporate.secretary@mithra.com), or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.

### Right to ask questions

The directors answer questions that are asked by the shareholders, in writing before the meeting, concerning their report or the agenda, in accordance with legal provisions. These questions may be asked prior to the General Meeting by email to the address [corporate.secretary@mithra.com](mailto:corporate.secretary@mithra.com) or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on **19 May 2023** at the latest.

Further information relating to the abovementioned right and the modalities for exercising them are available on the Company's website ([www.mithra.com](https://www.mithra.com)).

**Proxies**

Any shareholder who wish to vote for that meeting shall be represented by a proxy holder determined by the Company.

Shareholders wishing to be represented must send the completed and signed proxy<sup>1</sup> form to the Company **on 19 May 2023** at the latest, by email, fax or mail to Mithra's headquarter.

Shareholders wishing to vote by mail must send the completed and signed proxy form<sup>2</sup> to the Company **on 19 May 2023** at the latest, by email, fax or mail to Mithra's headquarter.

Further information on the exercise of this right is available on the Company's website ([www.mithra.com](http://www.mithra.com)). The proxy and voting forms may be obtained on the Company's website ([www.mithra.com](http://www.mithra.com)) or upon request at the Company's registered office, or by email to [corporate.secretary@mithra.com](mailto:corporate.secretary@mithra.com).

Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.

**Available documents**

All documents concerning the general meeting that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company's website ([www.mithra.com](http://www.mithra.com)) as from 25 April 2023. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company's registered office and/or, upon display of their securities, obtain copies of these documents free of charge.

Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to [corporate.secretary@mithra.com](mailto:corporate.secretary@mithra.com).

\*\*\*\*\*

---

<sup>1</sup> The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended

<sup>2</sup> See (1)

**For more information, please contact:**

**Alexandra Deschner:** +32 (0)4 349 28 22 – [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

**About Mithra**

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle<sup>®</sup>, Mithra is now focusing on its second product Donesta<sup>®</sup>, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 230 staff members and is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)*

*ESTELLE<sup>®</sup>, DONESTA<sup>®</sup> and MYRING<sup>®</sup> are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.*

**Important information**

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

A circular icon with a teal background and white text that reads "News Alerts".

News  
Alerts

Subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[LinkedIn](#) • [Twitter](#) • [Facebook](#)